Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential

Abstract

Aldehyde dehydrogenase (ALDH) activity is used to define normal hematopoietic stem cell (HSC), but its link to leukemic stem cells (LSC) in acute myeloid leukemia (AML) is currently unknown. We hypothesize that ALDH activity in AML might be correlated with the presence of LSC. Fifty-eight bone marrow (BM) samples were collected from AML (n=43), acute lymphoblastic leukemia (ALL) (n=8) and normal cases (n=7). In 14 AML cases, a high SSC loALDH br cell population was identified (ALDH +AML) (median: 14.89%, range: 5.65-48.01%), with the majority of the SSC loALDH br cells coexpressing CD34 +. In another 29 cases, there was undetectable (n=23) or rare (≥ 5%) (n=6) SSC lo ALDH br population (ALDH -AML). Among other clinicopathologic variables, ALDH +AML was significantly associated with adverse cytogenetic abnormalities. CD34 + BM cells from ALDH +AML engrafted significantly better in NOD/ SCID mice (ALDH +AML: injected bone 21.11±9.07%; uninjected bone 1.52±0.75% vs ALDH -AML: injected bone 1.77±1.66% (P=0.05); uninjected bone 0.23±0.23% (P=0.03)) with the engrafting cells showing molecular and cytogenetic aberrations identical to the original clones. Normal BM contained a small SSC loALDH br population (median: 2.92%, range: 0.92-5.79%), but none of the ALL cases showed this fraction. In conclusion, SSC loALDH br cells in ALDH + AML might denote primitive LSC and confer an inferior prognosis in patients.